LEADER 04136nam  22006615  450 
001 9910298445503321
005 20200705025335.0
010   $a94-017-7215-0
024 7 $a10.1007/978-94-017-7215-0
035   $a(CKB)3710000000501325
035   $a(EBL)4092703
035   $a(SSID)ssj0001583759
035   $a(PQKBManifestationID)16264409
035   $a(PQKBTitleCode)TC0001583759
035   $a(PQKBWorkID)14866235
035   $a(PQKB)10939017
035   $a(DE-He213)978-94-017-7215-0
035   $a(MiAaPQ)EBC4092703
035   $a(PPN)190531576
035   $a(EXLCZ)993710000000501325
100   $a20151103d2015      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aAdvances in Cancer Biomarkers $eFrom biochemistry to clinic for a critical revision /$fedited by Roberto Scatena
205   $a1st ed. 2015.
210  1$aDordrecht :$cSpringer Netherlands :$cImprint: Springer,$d2015.
215   $a1 online resource (361 p.)
225 1 $aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v867
300   $aDescription based upon print version of record.
311   $a94-017-7214-2 
320   $aIncludes bibliographical references at the end of each chapters and index.
327   $aPrelims -- I Generality.- II Tumor markers-a critical revision -- Enzymes.- Hormones -- Oncofetal proteins.- Cytokeratins -- Carbohydrate markers -- Blood group antigens.- Genetic markers -- Various protein markers -- III Perspectives.- The role of Circulating tumor Cells as tumor markers -- Index.
330   $aAt present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes.  Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simply  monitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirely  know their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and ?polluted? knowledge may have dramatic consequences for patient.  The aim of this book is to diffuse all aspects of cancer biomarkers, from their biochemical peculiarities to all clinical implications by passing through their physiology and pathophysiology. This critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time facilitating the research of new and more sensitive-specific signals of the cancer cell proliferation.
410  0$aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v867
606   $aCancer$xResearch
606   $aOncology
606   $aPharmacology
606   $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001
606   $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160
606   $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007
615  0$aCancer$xResearch.
615  0$aOncology.
615  0$aPharmacology.
615 14$aCancer Research.
615 24$aOncology.
615 24$aPharmacology/Toxicology.
676   $a610.28
702   $aScatena$b Roberto$4edt$4http://id.loc.gov/vocabulary/relators/edt
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910298445503321
996   $aAdvances in Cancer Biomarkers$92512272
997   $aUNINA